The FDA has removed the REMS program requirements for embryofetal toxicity risk from all endothelin receptor antagonist medications.

Armistice Capital holds 8.9M shares in Travere Therapeutics as rare kidney disease stock climbs 110% following FILSPARI's full FDA approval.

FILSPARI is the only oral, once-daily, non-immunosuppressive medication that directly targets glomerular injury in the kidney by blocking two critical pathways of IgAN disease progression ...

FILSPARI (sparsentan) is indicated to slow kidney function decline in adults with primary immunoglobulin A nephropathy (IgAN) who are at risk for disease progression.

If approved, FILSPARI would be the first and only FDA-approved treatment for FSGS, a rare kidney condition and a leading cause of kidney failure SAN DIEGO--(BUSINESS WIRE)-- Travere Therapeutics ...

Travere Therapeutics, Inc. (NASDAQ:TVTX) is one of the 13 Best Pharma Stocks to Buy According to Wall Street Analysts. On ...

New data from Phase 2 SPARTAN Study show antifibrotic and anti-inflammatory action of FILSPARI and its impact on B cell and complement pathways in IgAN Travere Therapeutics, Inc., (Nasdaq: TVTX ...

Ligand Partner Travere Therapeutics Receives Full FDA Approval for FILSPARI® (sparsentan), the Only Non-Immunosuppressive Treatment that Significantly Slows Kidney Function Decline in IgA Nephropathy ...

FILSPARI is an innovative, non-immunosuppressive, single-molecule, dual endothelin angiotensin receptor antagonist with high selectivity for the endothelin A receptor (ETAR) and the angiotensin II ...

England's NICE recommends FILSPARI® (sparsentan) as a treatment option for IgA nephropathy By Vifor International AG (CSL Vifor), Travere Therapeutics, Inc. May 23, 2025 Updated 1 hr ago CSL ...

SAN DIEGO, June 03, 2025--Travere Therapeutics today announced that the Company will present seven abstracts at the upcoming ERA Congress in Vienna, Austria, in June.